The overarching goal of StratCell is to facilitate clinical implementation of new innovative strategies for using gene-edited cytotoxic lymphocytes in cancer therapy.

Immunotherapy has become a cornerstone in cancer therapy that includes a broad array of strategies aiming to unleash, direct and boost the patients’ own immune system through adoptive transfer of expanded naturally circulating or genetically engineered cytotoxic lymphocytes. Despite the recent clinical breakthroughs, the field is still in its infancy and the potential for identifying new and more effective strategies is huge. 

Go to StratCell on Twitter